Buparlisib (BKM120, NVP-BKM120)

目录号:S2247

Buparlisib (BKM120, NVP-BKM120) Chemical Structure

Molecular Weight(MW): 410.39

Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂,在无细胞试验中作用于p110α/β/δ/γIC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34,mTOR,DNAPK 的作用效果下降,而对 PI4Kβ几乎没有活性。Phase 2。

规格 价格 库存 购买数量  
RMB 2227.95 现货
RMB 1400.12 现货
RMB 2607.65 现货
RMB 7928.28 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献42篇:

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂,在无细胞试验中作用于p110α/β/δ/γIC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34,mTOR,DNAPK 的作用效果下降,而对 PI4Kβ几乎没有活性。Phase 2。
特性 BKM120是可用于口服的生物有效的PI3K抑制剂。
靶点
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
Vps34 [1]
(Cell-free assay)
52 nM 116 nM 166 nM 262 nM 2.4 μM
体外研究

BKM120作用于解除PI3K调节的细胞系,包括A2780, U87MG, MCF7和DU145时,具有抗增殖活性,GI50为0.1-0.7 nM。[1] BKM120诱导多发性骨髓瘤细胞(ARP1, ARK, MM.1S, MM1.R和U266)凋亡,导致G1期细胞增多,S期细胞减少。BKM120诱导CD138+原代MM 细胞凋亡,且作用于CD138−基质细胞时毒性较低。BKM120可引起BimS的上调和XIAP的下调。[2]BKM120作用于人类胃癌细胞系,降低mTOR下游信号,具有抗增殖活性。BKM120作用于KRAS突变的胃癌细胞系,可以增强p-ERK或 p-STAT3。BKM120 和STAT3阻断剂联用, 作用于含突变KRAS的细胞,诱导凋亡,具有协同效应,但是作用于KRAS野生型细胞没有这种效果。[3]BKM120主要通过Aurora B激酶调节有丝分裂崩坏。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 Mo\KR5l1d3SxeHnjJGF{e2G7 NEPPUVk4OiCq M{XrTWROW09? MlKyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWNHPyClZXzsd{BmgHC{ZYPzbY5oKFCLM1vhcJBp[SCHNUS1T{BufXSjboSge4l1cCCJSUWwJI9nKDBwMECwNVU5KM7:TR?= NHu0RYQzPDlyMEK2Oi=>
DU145 NXm2TIdFS3m2b4TvfIlkKEG|c3H5 NI\jW3Q4OiCq MWDEUXNQ MkCwR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh\XiycnXzd4lv\yCOS1KxJI12fGGwdDD3bZRpKEeLNUCgc4YhOC5yMEC0N|Uh|ryP MoGwNlQ6ODB{Nk[=
A2780 NF2z[YdEgXSxdH;4bYMhSXO|YYm= NH:y[mI4OiCq NXzJOm5MTE2VTx?= NH7q[olEgXSxdH;4bYNqfHliYXfhbY5{fCCSVFXOMYRm\mmlaXXueEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIFfJOVAhd2ZiMD6wNFA3OzVizszN M1fGO|I1QTByMk[2
U87MG M1\PdWN6fG:2b4jpZ{BCe3OjeR?= NGm2epY4OiCq NV[0SVA1TE2VTx?= MmH6R5l1d3SxeHnjbZR6KGGpYXnud5QhWFSHTj3k[YZq[2mnboSgbJVu[W5iVUi3UWch[2WubIOge4l1cCCJSUWwJI9nKDBwMECwOlk5KM7:TR?= M3npXFI1QTByMk[2
A2780 MmfJSpVv[3Srb36gRZN{[Xl? MlfrNUBp MYrEUXNQ MWjJcohq[mm2aX;uJI9nKFCLM1utcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:|cHjvdplt[XSrb36ge4l1cCCHQ{WwJI9nKDBwMEW1JO69VQ>? M3fKUlI1QTByMk[2
DU145 NU\aUY06TnWwY4Tpc44hSXO|YYm= NIjhO5UyKGh? NWS2e4xwTE2VTx?= NVf1fnBEUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKESXMUS1JINmdGy|IHjhdoJwemmwZzDMT2IyKG23dHH0bY9vKHerdHigSWM2OCCxZjCwMlA4OyEQvF2= M13lRVI1QTByMk[2
A2780 MXzGeY5kfGmxbjDBd5NigQ>? NHPWZXgyKGh? Mn;3SG1UVw>? M4e5fmlvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCSVFXOMYRm\mmlaXXueEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIFXDOVAhd2ZiMD6wO|Qh|ryP NGjPR48zPDlyMEK2Oi=>
MCF7 MoLmSpVv[3Srb36gRZN{[Xl? NIq3SXEyKGh? MV3EUXNQ Ml31TY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiRUW0OWshdXW2YX70MY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJJdqfGhiRVO1NEBw\iByLkGg{txO NV;xUI5ZOjR7MECyOlY>
U87MG MkXNSpVv[3Srb36gRZN{[Xl? M{nmdVEhcA>? NGTWc3RFVVOR NXO3RXpbUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIGDUSW4u\GWoaXPp[Y51KGi3bXHuJHU5P02JIHPlcIx{KHerdHigSWM2OCCxZjCwMlE{KM7:TR?= NEm2[2ozPDlyMEK2Oi=>
A2780 M3SxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXO3NkBp M131UmROW09? NWm0VYk5TUN3ME2wMlUzKM7:TR?= NF;4VWczPDlyMEK2Oi=>
SKMES-1 MmXFR5l1d3SxeHnjJGF{e2G7 MWKxJO69VQ>? M{TRTlczKGh? NX3tXnNiUW6mdXPld{Bk\WyuIHTlZZRp MUOyOlAyOzNzOB?=
H596 M17IZWZ2dmO2aX;uJGF{e2G7 MYqxJO69VQ>? NInhU3hKdXCjaYLzJINmdGxibXnndoF1cW:w M3PYXVI3ODF|M{G4
HCC2450 MlPZSpVv[3Srb36gRZN{[Xl? MXexJO69VQ>? MlHMTY1x[Wm{czDj[YxtKGmwdnHzbY9v NVTaO|BoOjZyMUOzNVg>
A549 MkK0SpVv[3Srb36gRZN{[Xl? M4\m[|UxOCCwTR?= MWC0PEBp NUXtNYJtTE2VTx?= NX3RRppmUW6qaXLpeJMhSWu2IHHjeIl3[XSrb36= MX2yOVk{PzJ7OR?=
A549 NHPJNG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37NWFEh|ryP MmLlO|IhcA>? NF;iZZZFVVOR MWPJcohq[mm2czDj[YxtKGe{b4f0bC=> M3HSTlI2QTN5Mkm5
H522 NWnGUXk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoqyNUDPxE1? NH;KeY84OiCq MnfzSG1UVw>? MnnkTY5pcWKrdIOgZ4VtdCCpcn;3eIg> NWHOXFFLOjV7M{eyPVk>
LNCaP MWnGeY5kfGmxbjDBd5NigQ>? NEe5TWIyKM7:TR?= MnXhV5VxeHKnc4Pld{BxNUGNVDDs[ZZmdHN? NI\tdnQzPTN4MEe5PS=>
LNCaP95 MWjGeY5kfGmxbjDBd5NigQ>? M1HWdlEh|ryP M2jiSnN2eHC{ZYPz[ZMheC2DS2SgcIV3\Wy| NWX0cmxnOjV|NkC3PVk>
HCT-15 M4jqT2Fxd3Sxc3nzJGF{e2G7 MnrNNVAh|ryP NWPtPFd2PDhiaB?= MVvEUXNQ MUjJcoR2[2W|IHHwc5B1d3OrczDpckBJS1RvMUWgZ4VtdHNiaHHyZo92emmwZzDQTWs{S0FiaH;0d5BwfCCvdYTheIlwdg>? NHfLWGMzPTF3MkK0OS=>
HCT-116 M1rZWWFxd3Sxc3nzJGF{e2G7 MWWxNEDPxE1? MX:0PEBp M{jFfGROW09? MUfJcoR2[2W|IHHwc5B1d3OrczDpckBJS1RvMUG2JINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? M2Tic|I2OTV{MkS1
NCI-H460 NELzW3RCeG:2b4Ppd{BCe3OjeR?= NXrBXJRYOTBizszN MYC0PEBp NVLO[|dwTE2VTx?= MlXjTY5lfWOnczDhdI9xfG:|aYOgbY4hVkOLLVi0OlAh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= NFPUZ|UzPTF3MkK0OS=>
SKOV-3 NWjHPYV6SXCxdH;zbZMhSXO|YYm= MVOxNEDPxE1? MX60PEBp Mnu4SG1UVw>? MkDPTY5lfWOnczDhdI9xfG:|aYOgbY4hW0uRVj2zJINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? NF3WXFUzPTF3MkK0OS=>
BSY-1 MlTORZBwfG:|aYOgRZN{[Xl? MkDoNVAh|ryP NFnSOWI1QCCq NIGybolFVVOR MknTTY5lfWOnczDhdI9xfG:|aYOgbY4hSlO\LUGgZ4VtdHNiaHHyZo92emmwZzDQTWs{S0FiaH;0d5BwfCCvdYTheIlwdg>? NXvid4NYOjVzNUKyOFU>
MKN-1 NVzYOW42SXCxdH;zbZMhSXO|YYm= NVnqRnJLOTBizszN M3zhRlQ5KGh? MnfCSG1UVw>? M2XK[2lv\HWlZYOgZZBweHSxc3nzJIlvKE2NTj2xJINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? NFPiOogzPTF3MkK0OS=>
NCI-H522 M37JTGFxd3Sxc3nzJGF{e2G7 MkDnNVAh|ryP NX3qdXdOPDhiaB?= MYLEUXNQ MXTJcoR2[2W|IHHwc5B1d3Orcx?= NHfiWnkzPTF3MkK0OS=>
OVCAR-3 NHLYUm9CeG:2b4Ppd{BCe3OjeR?= M3LoTlExKM7:TR?= NETaboY1QCCq NHLCfG1FVVOR MWHJcoR2[2W|IHHwc5B1d3Orcx?= M2Dq[VI2OTV{MkS1
HBC-5 M4eySmFxd3Sxc3nzJGF{e2G7 MlKxNVAh|ryP NFjQb3U1QCCq NYLDPYg2TE2VTx?= M4SzeWlv\HWlZYOgZZBweHSxc3nz NUfYU4RMOjVzNUKyOFU>
RXF-631L NXX6UJlYSXCxdH;zbZMhSXO|YYm= MX2xNEDPxE1? MkSyOFghcA>? M2XwbWROW09? M4LxeGlv\HWlZYOgZZBweHSxc3nz M{fy[VI2OTV{MkS1
MKN-45 NUOybFI{SXCxdH;zbZMhSXO|YYm= MYGxNEDPxE1? NGjrcHU1QCCq NWrSNXY5TE2VTx?= NH\E[XZKdmS3Y3XzJIFxd3C2b4Ppdy=> NUfzSYZ[OjVzNUKyOFU>
BON-1 M36zbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUS1NFAhdk1? NXzuSIU2OTBiZB?= NYrHfY5PTE2VTx?= NIjwNmRKdmirYnn0d{Bk\WyuIHfyc5d1cA>? NHO5[3MzPTB{NkK5Ni=>
BON-1 NGH2[YJHfW6ldHnvckBCe3OjeR?= NWLjdZZJPTByIH7N MlrROEBp M{TQPGROW09? MmLuTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDUbJI{ODhiYX7kJHNmejR5Mx?= NHfUcVczPTB{NkK5Ni=>
QGP-1 NITHNYNHfW6ldHnvckBCe3OjeR?= MnjGOVAxKG6P MmfiOEBp NGXYeFRFVVOR NXj1SZBIUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVDDheEBVcHJ|MEigZY5lKFOnckS3Ny=> Ml\GNlUxOjZ{OUK=
Huh7 NGP2PW1HfW6ldHnvckBCe3OjeR?= MX[xJO69VQ>? MXqxJIg> MlfTSG1UVw>? NX3IUnRCUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVDDheEBU\XJ2N{S= NYfV[ZBnOjVyMES0NFM>
BNL MkjjSpVv[3Srb36gRZN{[Xl? M3P1OVEh|ryP MkTSNUBp M3\EN2ROW09? MmTITY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJHM3 M3;3dlI2ODB2NECz
MDA-MB-175 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELBdJAyKM7:TR?= NITrZ4o2KGR? Mn\uSG1UVw>? MnnoTWM2ODxzIN88US=> NGPqS3YzPDh5OUe5Oi=>
MDA-MB-134 MnK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDQUXZLOSEQvF2= NGPTWHc2KGR? NE\GcZVFVVOR NWDSdZJXUUN3MEyxJO69VQ>? MkHONlQ5Pzl5OU[=
HCC1500 NVT6N4JrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HJSVEh|ryP NH7EUIE2KGR? NFeyU|ZFVVOR NUfMSlJPUUN3MEyxJO69VQ>? NGDrVGwzPDh5OUe5Oi=>
EFM-19 M3Lrd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\4ZVEh|ryP NEDNdoc2KGR? NEfVT5hFVVOR NF[0b2ZKSzVyPEGg{txO MlS4NlQ5Pzl5OU[=
ZR-75-30 M3jvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13JfVEh|ryP MXO1JIQ> NILCbHRFVVOR NHjqfGNKSzVyPEGg{txO M4PWeVI1QDd7N{m2
MDA-MB-361 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvxbIkyKM7:TR?= MY[1JIQ> NIDibWNFVVOR NEnZdlJKSzVyPEGg{txO Mk\VNlQ5Pzl5OU[=
T-47D NH\ZOnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUCxJO69VQ>? NWDERVVDPSCm MULEUXNQ NEfzTmZKSzVyPEGg{txO MV[yOFg4QTd7Nh?=
SK-BR-3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLET3dDOSEQvF2= NV;nXXRRPSCm MkLnSG1UVw>? NVuzcHJtUUN3MEyxJO69VQ>? NGjCT|IzPDh5OUe5Oi=>
UACC-732 M2DSR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\oNUDPxE1? NWq0fIltPSCm NWDvTJBWTE2VTx?= M3;Zb2lEPTB:MTFOwG0> NFT2cnIzPDh5OUe5Oi=>
BT-474 M4XyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnPTZoyKM7:TR?= MYC1JIQ> NIPoU3pFVVOR M4\TPGlEPTB:MTFOwG0> MVqyOFg4QTd7Nh?=
HCC202 Mn3HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDiPWQyKM7:TR?= NVj3Z4Y4PSCm NFHDOnRFVVOR MV;JR|UxRDFizszN MWiyOFg4QTd7Nh?=
MCF7 MonYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYP1WpM5OSEQvF2= Ml71OUBl MYXEUXNQ MWHJR|UxRDFizszN MUSyOFg4QTd7Nh?=
MDA-MB-415 NGjpeHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTpS4d7OSEQvF2= MXm1JIQ> MVrEUXNQ NGXOR3VKSzVyPEGg{txO NGfBXYUzPDh5OUe5Oi=>
MDA-MB-453 NEXqdnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHPe|NzOSEQvF2= NE\LRmo2KGR? Mn\TSG1UVw>? MmrqTWM2ODxzIN88US=> NVHR[3J1OjR6N{m3PVY>
ZR-75-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nOeVEh|ryP M{GxNVUh\A>? M3rqb2ROW09? NV;F[lRbUUN3MEyxJO69VQ>? NYfae41FOjR6N{m3PVY>
HCC38 NYP4[mt6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX6xJO69VQ>? MVu1JIQ> MnLZSG1UVw>? Mm[yTWM2ODxzIN88US=> NXfmT3loOjR6N{m3PVY>
HCC1419 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP2NnEyKM7:TR?= M1zhcFUh\A>? MUDEUXNQ MlvGTWM2ODxzIN88US=> NFK2ToczPDh5OUe5Oi=>
UACC-812 MmPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX6xJO69VQ>? M1\U[VUh\A>? M1v4OGROW09? M{LoRmlEPTB:MTFOwG0> M3fJV|I1QDd7N{m2
HCC1187 M37FTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rKfVEh|ryP MnzROUBl NXOyUIhbTE2VTx?= MY\JR|UxRDFizszN M1z2c|I1QDd7N{m2
KPL-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV:xJO69VQ>? M{W4UVUh\A>? M{DrN2ROW09? M3fVemlEPTB:MTFOwG0> MnzNNlQ5Pzl5OU[=
SUM-225 MlKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYWxJO69VQ>? NVT0d5BiPSCm MXjEUXNQ NHjsdlZKSzVyPEGg{txO MoXINlQ5Pzl5OU[=
EFM-192A MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\HNUDPxE1? NULZNnY4PSCm NH7XVYhFVVOR NGrzOHNKSzVyPEGg{txO NGLjWlAzPDh5OUe5Oi=>
JIMT-1 NHnTbVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfMe4oyKM7:TR?= M3jUWlUh\A>? NH21fVlFVVOR NXfs[ZdQUUN3MEyxJO69VQ>? NIjqWZAzPDh5OUe5Oi=>
HCC1143 NXXPNVUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[xJO69VQ>? MXq1JIQ> NGnMbZBFVVOR NEjFU5lKSzVyPEGg{txO MXyyOFg4QTd7Nh?=
HCC2218 NUPBXlh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPBNUDPxE1? MlrwOUBl MnPsSG1UVw>? MnP0TWM2ODxzIN88US=> Mn7WNlQ5Pzl5OU[=
MDA-MB-468 Mkm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLKb5NOOSEQvF2= NV\kcoNCPSCm NYHtN|R7TE2VTx?= MoHrTWM2ODxzIN88US=> NFu0ZXgzPDh5OUe5Oi=>
BT-20 NVOxcHFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYCxJO69VQ>? NY\kXGZRPSCm M2f3[2ROW09? M2\6XWlEPTB:MTFOwG0> NFezSI8zPDh5OUe5Oi=>
MDA-MB-435 MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFqwU3cyKM7:TR?= MmPqOUBl M2G2cWROW09? NXm1OG5[UUN3MEyxJO69VQ>? M1Trb|I1QDd7N{m2
BT-549 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrzNUDPxE1? MWO1JIQ> MmrXSG1UVw>? NILLSodKSzVyPEGg{txO M3K5T|I1QDd7N{m2
HCC1806 NWX2SVhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TQeVEh|ryP M4HNfFUh\A>? NE\lbotFVVOR MmLUTWM2ODxzIN88US=> Mor3NlQ5Pzl5OU[=
HCC1937 Mlz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXlNIsyKM7:TR?= Mmn2OUBl NUi0fG5XTE2VTx?= MlnWTWM2ODxzIN88US=> NWjDbIIxOjR6N{m3PVY>
Hs578T MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXY[W0yKM7:TR?= NYXVfVc5PSCm NIr1c5dFVVOR NEnHcnhKSzVyPEGg{txO MXmyOFg4QTd7Nh?=
LN18 MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPZ[FAzOCEQvF2= M{XZeVczKGh? MoniSG1UVw>? MXzJR|UxRDVizszN M4\2N|I1PzRzMEe0
LN229 NVrCN286T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Xlc|IxKM7:TR?= NW\TUGxqPzJiaB?= NUG5OoJRTE2VTx?= M3m1TmlEPTB:NTFOwG0> M{PCVVI1PzRzMEe0
LNZ308 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnRNlAh|ryP MkXCO|IhcA>? MVPEUXNQ M1X0U2lEPTB:NTFOwG0> NHXYN5gzPDd2MUC3OC=>
T98G MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrLNlAh|ryP NGrOZnE4OiCq NEDtZXdFVVOR NWTrVpJJUUN3MEy1JO69VQ>? M3TqcVI1PzRzMEe0
U87 MnfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofWNlAh|ryP MVG3NkBp NH\XXplFVVOR MVLJR|UxRDVizszN MV[yOFc1OTB5NB?=
LN18 M3i5SmZ2dmO2aX;uJGF{e2G7 MYG1JO69VQ>? NUGyS5h[OjRiaB?= MlnZSG1UVw>? M3jsZmlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBCU1R? MX:yOFc1OTB5NB?=
LNZ308 MYPGeY5kfGmxbjDBd5NigQ>? M3uzWFUh|ryP NV\Kc2pLOjRiaB?= M3;Td2ROW09? NHjzN5ZKdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhSUuW NG\NOVczPDd2MUC3OC=>
Saos-2 M4DLZmZ2dmO2aX;uJGF{e2G7 MWm1NEDPxE1? M3nhdlQ5KGh? M3vyTWlvcGmkaYTzJINmdGxiaX72ZZNqd25? NYrxNGg4OjR5Mke2OlA>
MG-63 MU\GeY5kfGmxbjDBd5NigQ>? NXO1Zm1wPTBizszN MoO1OFghcA>? NHrycGdKdmirYnn0d{Bk\WyuIHnueoF{cW:w M2[4RlI1PzJ5Nk[w
SJSA-1 M1;l[mZ2dmO2aX;uJGF{e2G7 NWPKeWJSPTBizszN NYrtSpo6PDhiaB?= MoD0TY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>? NV2xZYVwOjR5Mke2OlA>
Saos-2 NV7NNIFqTnWwY4Tpc44hSXO|YYm= NWTuTZh1PTBizszN MoHHOFghcA>? M4noS2lvcGmkaYTzJI1ifHKreDDt[ZRidGyxcILveIVqdmG|ZT2yJIV5eHKnc4Ppc44> NEXhd28zPDd{N{[2NC=>
MG-63 MlLqSpVv[3Srb36gRZN{[Xl? MWm1NEDPxE1? NXjWUVBIPDhiaB?= NY\HT|ZLUW6qaXLpeJMhdWG2cnn4JI1mfGGubH;wdo91\WmwYYPlMVIh\XiycnXzd4lwdg>? MlTmNlQ4Ojd4NkC=
SJSA-1 MmLnSpVv[3Srb36gRZN{[Xl? M1nvVFUxKM7:TR?= NHPjNmU1QCCq M1XmeGlvcGmkaYTzJI1ifHKreDDt[ZRidGyxcILveIVqdmG|ZT2yJIV5eHKnc4Ppc44> MnzmNlQ4Ojd4NkC=
Saos-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTtOVAh|ryP M4r0SlQ5KGh? MWnJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? M2PhW|I1PzJ5Nk[w
MG-63 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nQe|UxKM7:TR?= MoXhOFghcA>? M1jnPWlvcGmkaYTzJINmdGxidnnhZoltcXS7 NVfVNm5YOjR5Mke2OlA>
SJSA-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nlfFUxKM7:TR?= NVfjT|hiPDhiaB?= MXrJcohq[mm2czDj[YxtKH[rYXLpcIl1gQ>? MWOyOFczPzZ4MB?=
FaDu MoWwSpVv[3Srb36gRZN{[Xl? NXH1ZZp3PSEQvF2= NIrFS4ozPCCq NX6wcllnTE2VTx?= MYXS[YR2[2W|IH;4fYdmdiClb37zeY1xfGmxbh?= MojENlQ3OzFzNEe=
EMT6 NUftcJV[TnWwY4Tpc44hSXO|YYm= M{DOT|Uh|ryP NF\jfGEzPCCq MlfKSG1UVw>? NHjoV|FT\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=> NH;UXFgzPDZ|MUG0Oy=>
HCT116 MVLGeY5kfGmxbjDBd5NigQ>? NI\xVII2KM7:TR?= Ml62NlQhcA>? NGntUY9FVVOR NIfJPHFT\WS3Y3XzJI95gWenbjDjc45{fW2ydHnvci=> MXuyOFY{OTF2Nx?=
U87 M4LUdWZ2dmO2aX;uJGF{e2G7 NY[5TnB4PSEQvF2= NGDuWJozPCCq NFXZZlBFVVOR M1HYOnJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u MlTPNlQ3OzFzNEe=
GBM MWnBdI9xfG:|aYOgRZN{[Xl? MXiy{txO MnizOFhp NFrWZ2JFVVOR MV;pcoR2[2WmIHjp[4hmeiCuZY\lcJMhd2ZiYYDvdJRwe2m|LDDhcoQh\GWlcnXhd4VlKGOnbHygeoli[mmuaYT5 MljyNlQ2ODB2OUK=
BON MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWKxMVXPxE1? MWi3Nog> Moqx[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvci=> NIS1eoYzPDR2M{WyNy=>
BON MmHhRZBweHSxc3nzJGF{e2G7 NUSxOnMxOS13zszN MUWyOIg> NF3pOFFqdmO{ZXHz[ZMh[XCxcITvd4l{ MXOyOFQ1OzV{Mx?=
H1975 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1W4e|AvOy17LkdOwG0> NFPSS204Omh? MU\EUXNQ MoDtTWM2OD1zLkO4Oe69VQ>? MV[yOFM{Pzh2Nh?=
H1975 M2izPWFxd3C2b4Ppd{BCe3OjeR?= NWn4bHRoOs7:TR?= MVuyOIg> MWXEUXNQ M4[5VYlv[3KnYYPld{BieG:ydH;zbZMhemG2ZTDzbYdvcW[rY3HueIx6 MUOyOFM{Pzh2Nh?=
T-ALL MV3BdI9xfG:|aYOgRZN{[Xl? NYrENW5M[mW2d3XlckAyNjRiYX7kJFUvOyCvTTDheEAzPGhiYX7kJFAvQSCjbnSgOU42KG2PIHH0JFQ5cCCrbjDkbYZn\XKnboSgZ4VtdCCuaX7l MnPhNlQhd3JiNEjo NUT4e|A{TE2VTx?= M2jEc4Fn\mWldIOgeIhmKFCLM1ugdIF1cHejeTDpckBVNUGOTDDj[YxtKGyrbnXz MV[yOFMyODd|Nh?=
BCR-ABL MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4S3OFAvOjVvMUFOwG0> MnvhOIQ> MmrGd4lodmmoaXPhcpRtgSCrbnjpZol1KGOnbHygdJJwdGmoZYLheIlwdg>? NX;neJlGOjR{NES2NVI>
LC-1/SQSF MUPGeY5kfGmxbjDBd5NigQ>? NYribVdIO87:TR?= MnWwNlRp Mn36SG1UVw>? NYO1Rop6\GWlcnXhd4UhVlKIMjDwdo91\WmwIHzleoVt M4rQcFI{QThyMEmz
Primary CLL cells NHzGdJZCeG:ydH;zbZMhSXO|YYm= MmPiNU0yOM7:TR?= NH3pZWg1QGh? M4Hqd4lv\HWlZYOgZZBweHSxc3nzJIlvKEOOTDDj[YxteyCrbnTldIVv\GWwdDDv[kBxem:pbn;zeIlkKG2jcnvldpM> NYLHVnUxOjN6NUC4NFc>
Primary CLL cells NUnoXZBpU2mwYYPlJGF{e2G7 NF7tT5oz|ryP MVezNI1qdg>? MXHk[YNz\WG|ZXSgVGk{UyCjY4Tpeol1gQ>? M{TrUlI{QDVyOEC3
Primary CLL cells MmXyR5l1d3SxeHnjJGF{e2G7 MX6y{txO NFjrfWwzPGh? MVHpcoR2[2W|IHPlcIwh[3m2b4TvfIlkcXS7 M3ThSlI{QDVyOEC3
human NSCLC cell lines MWrBdI9xfG:|aYOgRZN{[Xl? NHThPZkxNjF{NT20{txO NU\NeZNoOjSq M1HhWGROW09? NV;pWW9PUUN3MIOgdoFv\2W|IH\yc40hOC52LUNOwG0> NHfpSYUzOzV4MkS3Ni=>
human HCC cell lines NYnU[olwS2WubDD2bYFjcWyrdImgZZN{[Xl? M1flZlAvODB3LUJOwG0> NV7kN5VDPDiq MXLJR|UxRTIQvF2= MnLUNlM1QDl7OUm=
Huh7 NH3uTolMcW6jc3WgRZN{[Xl? NHLJcFEy|ryP MWm0PIg> M1f5d5Nq\26r77{BZ4FvfGy7IILl[JVk\XNicHjvd5Bpd3K7bHH0bY9vKG:oIFHreC=> MofoNlM1QDl7OUm=
SK-HEP1 Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnztNU0zOM7:TR?= NHG0Um04Omh? NV;OVmJqTE2VTx?= MYnJR|Ux97zeMd88US=> MViyN|Q4QTF|Nh?=
786-0 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYOxMVIx|ryP NGDybnE4Omh? MVvEUXNQ MmLZTWM2OO,:nEJOwG0> Mke1NlM1PzlzM{[=
JVM2 NH;ndW9EgXSxdH;4bYNqfHliYYPzZZk> MYqwMlIuOjEQvF2= MXO3Nog> NFnROFhFVVOR M1XaTmlEPTB;MD65{txO NUjuc3F7OjN{M{i2N|k>
EHEB Mli5R5l1d3SxeHnjbZR6KGG|c3H5 M1;j[|AvOi1{MN88US=> NVfaR4h2PzKq NU\BSHJJTE2VTx?= MY\JR|UxRTBwN988US=> MlvXNlMzOzh4M{m=
MEC2 MYfDfZRwfG:6aXPpeJkh[XO|YYm= M{G4NFAvOi1{MN88US=> NW\z[HR{PzKq NUGxTYtjTE2VTx?= NGPPUWdKSzVyPUCuO:69VQ>? NYrYWY51OjN{M{i2N|k>
primary B-CLL lymphocytes M{Lz[2Fxd3C2b4Ppd{BCe3OjeR?= NVvlNWtXUUN3MDDmc5Ih\WGlaDDwdolu[XK7IHPlcIwhdGmwZR?= MkC4NlRp MXnEUXNQ NYLzSlVJUUN3MP-8oFPPxE1iZn;yJIFtdCCyYYTp[Y51ew>? MkjSNlMzOzh4M{m=
primary B-CLL lymphocytes MYfLbY5ie2ViQYPzZZk> MmL5TWM2OCCob4Kg[YFkcCCycnntZZJ6KGOnbHygcIlv\Q>? MonINlRp NUDIW4lKcW6qaXLpeJMheDdyU{\LJEYhPEVvQmCxJIV5eHKnc4Ppc44> NIDSfYEzOzJ|OE[zPS=>
human NSCLC NVTwOZJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnLNE42NTMQvF2= MXi3Nog> MUPJR|UxRTIQvF2= MofTNlI4QDF|OUO=
human NSCLC MoTpT4lv[XOnIFHzd4F6 MYix{txO NYfZ[3hEOjSq NHH4PHBqdmirYnn0d{B1cGViQXv0M41VV1Jic3nncoFtcW6pIIDheIh4[XliYYSgN4gh[W[2ZYKgeJJm[XSvZX70 MYWyNlc5OTN7Mx?=
Y1 cell line MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHW4XpIxNjIQvF2vNe69VQ>? M1HYdlI1cA>? NVm4b3lUTE2VTx?= NYDE[HVKcW6qaXLpeJMhPjExvJWgZ4VtdCC4aXHibYxqfHliaX6gUZlkNVOldIKteJJidnOoZXP0[YQh[2WubIO= M2m0blIzPjl{OUC0
PIK3CA-mutant MCF7 NWLkSHlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEmwe2hIUTVyPUG2NOKyQTGwTf-8kGxFPTB;OUiwxtEzPzOwTR?= MYW3Nog> M{PZTGdKPTB;MU[wxtE6OW6P78{MUGQ2OD17OEFCtVI4O26P MmfrNlI3PTN7Nke=
PIK3CA-mutant MCF7 NVHkVWF{U2mwYYPlJGF{e2G7 Mn75TWM2OD1zMUVCtVNvVQ>? NEXyOIM4Omh? NWnWNWlTUUN3ME2xNVTDuTOwTTDpckBz\WS3Y3nu[{BCc3RicHjvd5Bpd3K7bHH0bY9vKGyndnXsdy=> MoLDNlI3PTN7Nke=
MCF7-myr-Akt M1X1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrHTVUxRTJ7OdMxOlhvVe,:jFzEOVDwxJ5zMDywNFBvVQ>? NX3LcZZDPzKq NFPiOWRIUTVyPUK5PeKyPjiwTf-8kGxFPTExvK6xNEwxODCwTR?= NVP4UIZPOjJ4NUO5Olc>
colon cancer cell lines NYn6cVJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHT4RZMxNTFyzszN MVy3Nog> NYXWS3o{TE2VTx?= MYPJR|UxRTIQvF2= NVvDNmhrOjJ3NEO4OVc>
gastric cancer cell lines M2fDVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPXNE0yOM7:TR?= MmfIO|Jp NX\PcJhbTE2VTx?= MULJR|UxRTJvNd88US=> NYPNOGFROjJ3NEO4OVc>
HCT-116/HT-29/MKN-45 MVXBdI9xfG:|aYOgRZN{[Xl? NFzyboIz|ryP NGXvUVA1QGh? NEe3TWd{cGmodDDpckBIOiCyaHHz[S=> M1fHOlIzPTR|OEW3
HT-29 and HCT-116 NUjkcFRRS2G|cHHz[UBie3OjeR?= NYTGdo1mPc7:TR?= NYK5[GJSOjSq NIjLSYtqdmS3Y3XzJINie3Cjc3WgZYN1cX[rdIm= NYroS|B7OjJ3NEO4OVc>
MM cell lines NYnJfZlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTZWplzOTEQvF2= MmTrNlRp NGX3fY1FVVOR MXHJR|UxKH[jcnnld{BidW:wZzDkbYZn\XKnboSgZ4VtdCCuaX7ld{BqdiC2aX3lJIFv\CCmb4PlJIRmeGWwZHXuZ4U> NEfVRWszOjJyN{S4OS=>
ARP-1 NXu0fWp1SXCxcITvd4l{KEG|c3H5 NUTEUIdPOTEQvF2= NGT3c3IzPGh? MVPEUXNQ MUfpcoR2[2W|IF3NJINmdGxiYYDvdJRwe2m|IITodo92\2hiY3HzdIF{\SCjY4TpeoF1cW:w M1rOTFIzOjB5NEi1
SNU-601 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DjT|czcA>? NVqwT2Y{TE2VTx?= NV;TPFFRUUN3ME2wMlgyPsLzMD6wOlPPxE1? MYqyNlE2QThzNB?=
SNU-1 M1Xa[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlraO|Jp MWjEUXNQ MXLJR|UxRTFwMEiyxtExNjB{ON88US=> MmrSNlIyPTl6MUS=
SNU-668 MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDVO|Jp M{\2b2ROW09? NFrwXYFKSzVyPUGuOVc6yrFyLkC3OO69VQ>? NF3ZPFczOjF3OUixOC=>
AGS NIW5SHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUK3Nog> NETuXWdFVVOR NV3tXmQ5UUN3ME2xMlcyPMLzMD6xNVfPxE1? NInROGgzOjF3OUixOC=>
SNU-216 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXidXExPzKq NHv1VGFFVVOR NWrYbZJtUUN3ME2yMlY6OsLzMD6wPFLPxE1? NVjRdm5pOjJzNUm4NVQ>
SNU-5 MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nUOFczcA>? MoXQSG1UVw>? M2XEfmlEPTB;MT6zOVHDuTBwMEmx{txO MWKyNlE2QThzNB?=
SNU-638 M{\sXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWe3Nog> MlfESG1UVw>? MYrJR|UxRTJwMkiyxtExNjB3M988US=> NXjjSFNQOjJzNUm4NVQ>
SNU-16 M1O3[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGKzcXg4Omh? NG\QXIZFVVOR M2Cz[mlEPTB;MT61O|PDuTBwMECx{txO NGrRe5ozOjF3OUixOC=>
SNU-484 M3vwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHUR3M5PzKq NVLSRY45TE2VTx?= MYHJR|UxRTFwN{K4xtExNjB2Nd88US=> Mm\LNlIyPTl6MUS=
SNU-620 M4HPSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXG3Nog> M1y0b2ROW09? MkmxTWM2OD1{LkmzPeKyOC5yMEJOwG0> MVSyNlE2QThzNB?=
SNU-719 NEDISoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXm3Nog> NYC5RXJHTE2VTx?= M3;IWGlEPTB;Mz6wN|fDuTBwMEOy{txO MVOyNlE2QThzNB?=
glioma cell lines NEjqS3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n2NFczcA>? M3iwWGlEPTB;MT2y{txO MlS3NlIxPjVyOEC=
U87 MXnBdI9xfG:|aYOgRZN{[Xl? M2XoSFLPxE1? MXi3Nog> MUnpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGGwZDDjcIVifmWmIGDBVnAh[W6mIHPhd5Bie2VvMx?= MX6yNlA3PTB6MB?=

... Click to View More Cell Line Experimental Data

体内研究 BKM120按30, 60, 或100 mg/kg剂量作用于A2780移植瘤,完全抑制pAKTser473。BKM120按 30和 60 mg/kg剂量作用于U87MG神经胶质瘤模型,显示抗癌活性。[1]BKM120每天按5μM/kg剂量处理具有持久生命力的ARP1 SCID鼠模型,导致肿瘤体积和K链水平明显降低。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[2]
+ 展开

PI3K 生化实验(ATP 消耗实验):

BKM120溶于DMSO中,按每孔1.25 µL直接加到黑色384孔板上。开始反应, 25 µL 10nM PI3K和5 µg/mL 1-α-磷酸肌醇(PI)加到实验 buffer (10 mM Tris pH 为7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT,及0.05% CHAPS),然后加到每孔中,随后在实验buffer中加入25 µL 2 µM ATP。反应进行直到50% ATP被消耗,然后加入25 µL KinaseGlo溶液终止反应。终止的反应温育5分钟,然后通过荧光测定残留的ATP。
细胞实验:[1]
+ 展开
  • Cell lines: A2780细 胞
  • Concentrations: 0-6.6 μM
  • Incubation Time: 3天
  • Method: A2780细胞培养在含10% FBS,L-谷氨酸,丙酮酸钠和抗生素的DMEM培养基上。细胞按每孔103个细胞的密度接种在相同培养基上,温育3到5小时。稀释溶于20 mM DMSO中的BKM120。2 µL稀释的BKM120溶液加到细胞培养基上, (浓度为0-6.6 µM)。等体积(100 µL)溶液加到96孔板中,在37oC下温育3天。使用Trilux读取荧光值而测定抑制细胞增殖的效果
    (Only for Reference)
动物实验:[1]
+ 展开
  • Animal Models: 携带U87MG 和A2780移植瘤的雌性裸鼠
  • Formulation: 15% Captisol
  • Dosages: ~60 mg/kg
  • Administration: 每天口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.8 mM)
Ethanol 2 mg/mL (4.87 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+ddH2O
15mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 410.39
化学式

C18H21F3N6O2

CAS号 944396-07-0
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02756247 Active not recruiting Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Diffuse Large B Cell Lymphoma Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs LLC|Novartis Pharmaceuticals May 2016 Phase 1
NCT02756247 Active not recruiting Lymphoma|Mantle Cell Lymphoma|Follicular Lymphoma|Diffuse Large B Cell Lymphoma Memorial Sloan Kettering Cancer Center|Janssen Scientific Affairs LLC|Novartis Pharmaceuticals May 2016 Phase 1
NCT02614508 Active not recruiting Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Emory University|Novartis January 2016 Phase 1
NCT02614508 Active not recruiting Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Emory University|Novartis January 2016 Phase 1
NCT01613677 Withdrawn Treatment for Metastatic or Locally Advanced Cervical Cancer Novartis Pharmaceuticals|Novartis November 2015 Phase 2
NCT01613677 Withdrawn Treatment for Metastatic or Locally Advanced Cervical Cancer Novartis Pharmaceuticals|Novartis November 2015 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

Tags: 购买Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120)供应商 | 采购Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120)价格 | Buparlisib (BKM120, NVP-BKM120)生产 | 订购Buparlisib (BKM120, NVP-BKM120) | Buparlisib (BKM120, NVP-BKM120)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID